ADHD
MCID: ATT013
MIFTS: 65

Attention Deficit-Hyperactivity Disorder (ADHD)

Categories: Genetic diseases, Mental diseases, Neuronal diseases

Aliases & Classifications for Attention Deficit-Hyperactivity Disorder

MalaCards integrated aliases for Attention Deficit-Hyperactivity Disorder:

Name: Attention Deficit-Hyperactivity Disorder 56 53 39
Attention Deficit Hyperactivity Disorder 40 12 74 25 36 29 6 42 15 62 17 71
Adhd 56 40 12 25 53 3 15
Attention Deficit Disorder 12 25 54 71
Attention Deficit-Hyperactivity Disorder, Susceptibility to 56 13 6
Attention Deficit Disorder with Hyperactivity 25 43
Hyperkinetic Disorder 12 25
Attention-Deficit/hyperactivity Disorder, Predominantly Inattentive Type 71
Attention Deficit Disorder of Childhood with Hyperactivity 25
Attention Deficit Disorder with Hyperactivity Syndrome 25
Attention-Deficit/hyperactivity Disorder 25
Attention-Deficit Hyperactivity Disorder 54
Hyperactivity of Childhood 56
Hyperkinetic Syndrome 25
Attention Deficit 25
Addh 25
Add 25

Characteristics:

OMIM:

56
Inheritance:
autosomal dominant


HPO:

31
attention deficit-hyperactivity disorder:
Inheritance autosomal dominant inheritance


Classifications:



External Ids:

Disease Ontology 12 DOID:1094
OMIM 56 143465
KEGG 36 H01895
MeSH 43 D001289
NCIt 49 C35092
ICD10 32 F90 F90.0 F90.9
MedGen 41 C1263846
UMLS 71 C0041671 C0339002 C1263846

Summaries for Attention Deficit-Hyperactivity Disorder

Genetics Home Reference : 25 Attention-deficit/hyperactivity disorder (ADHD) is a behavioral disorder that typically begins in childhood and is characterized by a short attention span (inattention), an inability to be calm and stay still (hyperactivity), and poor impulse control (impulsivity). Some people with ADHD have problems with only inattention or with hyperactivity and impulsivity, but most have problems related to all three features. In people with ADHD, the characteristic behaviors are frequent and severe enough to interfere with the activities of daily living such as school, work, and relationships with others. Because of an inability to stay focused on tasks, people with inattention may be easily distracted, forgetful, avoid tasks that require sustained attention, have difficulty organizing tasks, or frequently lose items. Hyperactivity is usually shown by frequent movement. Individuals with this feature often fidget or tap their foot when seated, leave their seat when it is inappropriate to do so (such as in the classroom), or talk a lot and interrupt others. Impulsivity can result in hasty actions without thought for the consequences. Individuals with poor impulse control may have difficulty waiting for their turn, deferring to others, or considering their actions before acting. More than two-thirds of all individuals with ADHD have additional conditions, including insomnia, mood or anxiety disorders, learning disorders, or substance use disorders. Affected individuals may also have autism spectrum disorder, which is characterized by impaired communication and social interaction, or Tourette syndrome, which is a disorder characterized by repetitive and involuntary movements or noises called tics. In most affected individuals, ADHD continues throughout life, but in about one-third of individuals, signs and symptoms of ADHD go away by adulthood.

MalaCards based summary : Attention Deficit-Hyperactivity Disorder, also known as attention deficit hyperactivity disorder, is related to attention deficit-hyperactivity disorder 2 and bipolar disorder, and has symptoms including seizures, tremor and back pain. An important gene associated with Attention Deficit-Hyperactivity Disorder is DRD4 (Dopamine Receptor D4), and among its related pathways/superpathways are Dopaminergic synapse and Serotonergic synapse. The drugs Reboxetine and Sertraline have been mentioned in the context of this disorder. Affiliated tissues include brain, testes and cortex, and related phenotypes are hyperactivity and attention deficit hyperactivity disorder

Disease Ontology : 12 A specific developmental disorder that is characterized by co-existence of attentional problems and hyperactivity, with each behavior occurring infrequently alone and symptoms starting before seven years of age.

MedlinePlus : 42 Is it hard for your child to sit still? Does your child act without thinking first? Does your child start but not finish things? If so, your child may have attention deficit hyperactivity disorder (ADHD). Nearly everyone shows some of these behaviors at times, but ADHD lasts more than 6 months and causes problems in school, at home and in social situations. ADHD is more common in boys than girls. It affects 3-5 percent of all American children. The main features of ADHD are Inattention Hyperactivity Impulsivity No one knows exactly what causes ADHD. It sometimes runs in families, so genetics may be a factor. There may also be environmental factors. A complete evaluation by a trained professional is the only way to know for sure if your child has ADHD. Treatment may include medicine to control symptoms, therapy, or both. Structure at home and at school is important. Parent training may also help. NIH: National Institute of Mental Health

CDC : 3 ADHD is one of the most common neurodevelopmental disorders of childhood. It is usually first diagnosed in childhood and often lasts into adulthood. Children with ADHD may have trouble paying attention, controlling impulsive behaviors (may act without thinking about what the result will be), or be overly active.

NINDS : 53 Attention deficit-hyperactivity disorder (ADHD) is a neurobehavioral disorder that affects 3-5 percent of all American children. It interferes with a person's ability to stay on a task and to exercise age-appropriate inhibition (cognitive alone or both cognitive and behavioral). Some of the warning signs of ADHD include failure to listen to instructions, inability to organize oneself and school work, fidgeting with hands and feet, talking too much, leaving projects, chores and homework unfinished, and having trouble paying attention to and responding to details. There are several types of ADHD: a predominantly inattentive subtype, a predominantly hyperactive-impulsive subtype, and a combined subtype. ADHD is usually diagnosed in childhood, although the condition can continue into the adult years.

KEGG : 36 Attention-deficit hyperactivity disorder (ADHD) is a common psychiatric disorder first diagnosed in childhood and frequently persistent throughout adult life. The disorder is classically characterized by symptoms of inattention, impulsivity, and hyperactivity. Many children with ADHD go on to have problems related to education, social functioning, and/or other mental illness as adolescents and young adults. Although heritability estimates are consistently high, ADHD is a genetically complex disorder characterized by multifactorial inheritance involving numerous genes of moderate effect. Reports implicate variants of genes important for the synthesis, uptake, transport and receptor binding of dopamine in the etiology of ADHD. And interaction between the dopamine and serotonin systems has been implicated in both the pathophysiology of ADHD and the mechanism of action of widely used stimulant compounds.

PubMed Health : 62 About attention deficit hyperactivity disorder: Attention deficit hyperactivity disorder, ADHD, is a mental disorder in which children are especially inattentive, impulsive or hyperactive. “Inattentive” refers to children who have difficulties focusing and are easily distracted. Overly “impulsive” children act in a way that is extremely rash, inconsiderate, careless or impatient for their age. “Hyperactive” describes children who are restless or constantly fidgeting – for instance, they may not be able to sit still during school lessons, and get up and walk around the classroom a lot instead. Severe ADHD can cause major problems in the life and everyday routine of both the child and their parents and brothers and sisters: Because children with ADHD behave differently than expected, they often cause trouble. They need a lot of attention. They find it more difficult to learn because of their short attention span. ADHD may also be accompanied by other kinds of mental disorders. The number of children being diagnosed with ADHD has increased in recent years. Some people are wary of this development and doubt that ADHD is really that common. They are worried that a lot of children who are diagnosed with ADHD are simply a little overactive, but otherwise healthy. A wrong diagnosis may lead to unnecessary treatment. Being wrongly labelled as mentally ill may also affect a child’s self-esteem. But there are also children and teenagers who actually have ADHD but are not diagnosed with it. This can also have a negative effect, because they may not get treatment that could help them. So it is very important to take the time to look into things so ADHD can be ruled out or diagnosed.

Wikipedia : 74 Attention deficit hyperactivity disorder (ADHD) is a mental disorder of the neurodevelopmental type. It... more...

More information from OMIM: 143465

Related Diseases for Attention Deficit-Hyperactivity Disorder

Diseases in the Attention Deficit-Hyperactivity Disorder family:

Attention Deficit-Hyperactivity Disorder 1 Attention Deficit-Hyperactivity Disorder 2
Attention Deficit-Hyperactivity Disorder 3 Attention Deficit-Hyperactivity Disorder 4

Diseases related to Attention Deficit-Hyperactivity Disorder via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 1289)
# Related Disease Score Top Affiliating Genes
1 attention deficit-hyperactivity disorder 2 35.8 DRD5 ADHD2
2 bipolar disorder 34.5 TPH2 SLC6A3 MECP2 DRD5 DRD4 COMT
3 gilles de la tourette syndrome 34.5 SLC6A3 DRD5 DRD4 COMT
4 impulse control disorder 34.2 SLC6A3 DRD5 DRD4 COMT
5 autism 33.9 TPH2 TCF20 SLC9A9 SLC6A3 MECP2 MAP1B
6 major depressive disorder 33.9 TPH2 SLC6A3 DRD4 COMT
7 autism spectrum disorder 33.8 TPH2 TCF20 SLC6A3 MECP2 MAP1B DRD5
8 oppositional defiant disorder 33.6 TPH2 SLC6A3 DRD4 COMT
9 conduct disorder 33.6 SLC6A3 DRD5 DRD4 COMT
10 tic disorder 33.4 TPH2 SLC6A3 DRD5 DRD4 COMT
11 substance abuse 33.3 SLC6A3 DRD5 DRD4 COMT
12 personality disorder 33.3 TPH2 SLC6A3 DRD4 COMT
13 anxiety 33.2 TPH2 SLC6A3 DRD4 COMT
14 pervasive developmental disorder 33.2 TCF20 SLC9A9 SLC6A3 MECP2 DRD5 DRD4
15 obsessive-compulsive disorder 33.2 TPH2 SLC6A3 HIVEP1 DRD4 COMT CDK20
16 mental depression 33.1 TPH2 SLC6A3 DRD4 COMT
17 alacrima, achalasia, and mental retardation syndrome 33.1 VPS13B TCF20 SCAPER MECP2 C12orf57 C12orf4
18 mood disorder 33.0 TPH2 SLC6A3 DRD4 COMT
19 alcohol dependence 33.0 TPH2 SLC6A3 DRD5 DRD4 COMT
20 borderline personality disorder 32.8 TPH2 SLC6A3 COMT
21 restless legs syndrome 32.8 SLC6A3 DRD5 DRD4 COMT
22 antisocial personality disorder 32.8 SLC6A3 DRD4 COMT
23 tobacco addiction 32.7 SLC6A3 DRD5 DRD4 COMT
24 psychotic disorder 32.6 TPH2 SLC6A3 DRD5 DRD4 COMT
25 substance dependence 32.6 SLC6A3 DRD5 DRD4 COMT
26 schizophrenia 32.5 TPH2 SLC6A3 MECP2 MAP1B DRD5 DRD4
27 avoidant personality disorder 32.5 SLC6A3 DRD4
28 panic disorder 32.5 TPH2 SLC6A3 DRD5 DRD4 COMT
29 disease of mental health 32.4 SLC6A3 MECP2 DRD5 DRD4 COMT
30 cocaine dependence 32.4 TPH2 SLC6A3 COMT
31 bruxism 32.4 MECP2 DRD5 DRD4
32 visual epilepsy 32.3 MECP2 HIVEP1 CDK20 C12orf57
33 periodic limb movement disorder 32.2 DRD5 DRD4
34 pathological gambling 32.1 SLC6A3 DRD5 DRD4 COMT
35 chronic tic disorder 32.1 DRD5 DRD4
36 movement disease 32.1 SLC6A3 DRD5 DRD4
37 separation anxiety disorder 32.1 SLC6A3 DRD4
38 bipolar i disorder 32.1 TPH2 DRD4 COMT
39 migraine with or without aura 1 32.0 SLC6A3 DRD5 DRD4 COMT
40 amphetamine abuse 31.6 SLC6A3 DRD5 DRD4
41 cannabis abuse 31.6 DRD4 COMT
42 heroin dependence 31.5 SLC6A3 DRD4 COMT
43 schizotypal personality disorder 31.3 DRD4 COMT
44 specific developmental disorder 31.3 SLC6A3 MECP2 DRD5 DRD4 COMT
45 premature ejaculation 31.0 SLC6A3 COMT
46 delusional disorder 31.0 SLC6A3 DRD5 DRD4
47 paranoid schizophrenia 30.7 TPH2 DRD5 COMT
48 language delay and attention deficit-hyperactivity disorder/cognitive impairment with or without cardiac arrhythmia 13.1
49 attention deficit-hyperactivity disorder 1 13.0
50 attention deficit-hyperactivity disorder 4 12.9

Graphical network of the top 20 diseases related to Attention Deficit-Hyperactivity Disorder:



Diseases related to Attention Deficit-Hyperactivity Disorder

Symptoms & Phenotypes for Attention Deficit-Hyperactivity Disorder

Human phenotypes related to Attention Deficit-Hyperactivity Disorder:

31
# Description HPO Frequency HPO Source Accession
1 hyperactivity 31 HP:0000752
2 attention deficit hyperactivity disorder 31 HP:0007018

Symptoms via clinical synopsis from OMIM:

56
Neuro:
hyperactivity

Misc:
male:female ratio 8:1

Clinical features from OMIM:

143465

UMLS symptoms related to Attention Deficit-Hyperactivity Disorder:


seizures, tremor, back pain, pain, headache, syncope, chronic pain, sciatica, vertigo/dizziness, sleeplessness

Drugs & Therapeutics for Attention Deficit-Hyperactivity Disorder

PubMed Health treatment related to Attention Deficit-Hyperactivity Disorder: 62

Before any treatment is started, the doctor will talk about what ADHD is and how everyone can best cope with it. As well as the parents and their child, teachers and preschool teachers may also be there too. It may then turn out that there is no urgent need for treatment. When deciding whether or not treatment is necessary, it is important to consider how much of a problem the behavior is for the child and their parents, and whether things like their performance at school are suffering as a result. If a child only has a mild form of ADHD that does not affect his or her life too much, it might be enough to complete a parent training and education program on dealing with ADHD. These programs can be taken as a class with an instructor or done on your own using written material. If a child has moderate or severe ADHD that is causing problems at school and in their social environment, it may be helpful to try interventions at school or have family or behavioral therapy . The type of help that will be most effective will depend on the child’s age, whether they tend to be more inattentive or more hyperactive, and what areas of their life the ADHD has the greatest impact on. Medication can relieve ADHD symptoms. It is mainly considered for the treatment of more severe ADHD when psychological and educational approaches are not effective enough. Medicine containing the drug methylphenidate is the most commonly used medication. If methylphenidate does not work or cannot be used for other reasons, the drugs atomoxetine , dexamfetamine or lisdexamfetamine may be used instead. Treatment at a psychosomatic or psychiatric hospital for children and teenagers may be a good idea for children who are extremely hyperactive and impulsive and have great difficulty coping in daily life, or can no longer cope at all. Hospital treatment may also be needed if the child has other severe mental disorders too.

Drugs for Attention Deficit-Hyperactivity Disorder (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 415)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Reboxetine Approved, Experimental Phase 4 71620-89-8, 98769-81-4 123628 65856
2
Sertraline Approved Phase 4 79617-96-2 68617
3
Lithium carbonate Approved Phase 4 554-13-2
4
Lamotrigine Approved, Investigational Phase 4 84057-84-1 3878
5
Clonidine Approved Phase 4 4205-90-7 2803
6
Memantine Approved, Investigational Phase 4 19982-08-2 4054
7
Amantadine Approved Phase 4 768-94-5 2130
8
Galantamine Approved Phase 4 357-70-0 9651
9
Risperidone Approved, Investigational Phase 4 106266-06-2 5073
10
Olanzapine Approved, Investigational Phase 4 132539-06-1 4585
11
Methamphetamine Approved, Illicit Phase 4 537-46-2 10836
12
Riluzole Approved, Investigational Phase 4 1744-22-5 5070
13
Pramipexole Approved, Investigational Phase 4 104632-26-0 59868 119570
14
Cyproheptadine Approved Phase 4 129-03-3 2913
15
Amphetamine Approved, Illicit, Investigational Phase 4 300-62-9 5826 3007
16
Histamine Approved, Investigational Phase 4 51-45-6 774
17
gamma-Aminobutyric acid Approved, Investigational Phase 4 56-12-2 119
18
Buprenorphine Approved, Illicit, Investigational, Vet_approved Phase 4 52485-79-7 40400 644073
19
Valproic acid Approved, Investigational Phase 4 99-66-1 3121
20
Oxcarbazepine Approved Phase 4 28721-07-5 34312
21
Methylprednisolone Approved, Vet_approved Phase 4 83-43-2 6741
22
Methylprednisolone hemisuccinate Approved Phase 4 2921-57-5
23
Diazepam Approved, Illicit, Investigational, Vet_approved Phase 4 439-14-5 3016
24
Prednisolone Approved, Vet_approved Phase 4 50-24-8 5755
25 Prednisolone acetate Approved, Vet_approved Phase 4 52-21-1
26
Levetiracetam Approved Phase 4 102767-28-2 441341
27
Carbamazepine Approved, Investigational Phase 4 298-46-4 2554
28
Prednisolone phosphate Approved, Vet_approved Phase 4 302-25-0
29
Guanfacine Approved, Investigational Phase 4 29110-47-2 3519
30
Dextroamphetamine Approved, Illicit Phase 4 51-64-9 5826
31
Naltrexone Approved, Investigational, Vet_approved Phase 4 16590-41-3 5360515
32
Ethanol Approved Phase 4 64-17-5 702
33
Bupropion Approved Phase 4 34911-55-2, 34841-39-9 444
34
Varenicline Approved, Investigational Phase 4 249296-44-4 5310966
35
Butyric Acid Experimental, Investigational Phase 4 107-92-6 264
36
Prednisolone hemisuccinate Experimental Phase 4 2920-86-7
37 Renal Agents Phase 4
38 Antiparasitic Agents Phase 4
39 Antiprotozoal Agents Phase 4
40 Anti-Infective Agents, Urinary Phase 4
41 Antimalarials Phase 4
42 Sulfalene Phase 4
43 Sympatholytics Phase 4
44 Protective Agents Phase 4
45 Tranquilizing Agents Phase 4
46 Serotonin Agents Phase 4
47 Antipsychotic Agents Phase 4
48 Dopamine Antagonists Phase 4
49 Serotonin Antagonists Phase 4
50 Antiparkinson Agents Phase 4

Interventional clinical trials:

(show top 50) (show all 1521)
# Name Status NCT ID Phase Drugs
1 Functional Brain Markers and Predictors of Treatment Response Associated With Norepinephrine System Genes in ADHD Unknown status NCT00862108 Phase 4 Methylphenidate
2 Comparing Treatment With Melatonin to Treatment With Stimulants (Methylphenidate) in Children With Attention Deficit Hyperactivity Disorder and Sleep Difficulties Unknown status NCT01393574 Phase 4 Melatonin;Methylphenidate
3 A 12-Month Open Label Safety Study of Methylphenidate Hydrochloride Extended-Release Capsules (Aptensio XR®) in Children Ages 4-5 Years Diagnosed With Attention-Deficit/Hyperactivity Disorder (ADHD) Unknown status NCT02677519 Phase 4 Aptensio XR
4 Comprehensive Pathophysiological Study Based on the Core Neurocognitive Deficits and Development of Biological Markers of Treatment Response in Attention Deficit Hyperactivity Disorder Unknown status NCT02623114 Phase 4 methylphenidate;atomoxetine
5 The Effect of a Once Daily Evening Dose of Atomoxetine (ATX) on ADHD-Related Insomnia in Children and Adolescents Unknown status NCT00252278 Phase 4 atomoxetine
6 A Randomized , Controlled, Doulbe Blind Placebo Trial To Evaluate The Efficacy and the Tolerance of an Omega 3 Fatty Acids Supplementation in ADHD Children Unknown status NCT00770627 Phase 4
7 Study of Associated Gene Polymorphisms With Atomoxetine Response Prediction in ADHD Treatment Unknown status NCT01339286 Phase 4 atomoxetine
8 Aggressive Behaviour in Children With Tourette's Syndrome (TS) and Comorbid Attention Deficit Hyperactivity Disorder (ADHD) Unknown status NCT00152750 Phase 4 APO-clonidine
9 A Study to Identify the Peripheral Biomarkers of Symptomatology, Neurocognitive Functions, and Medication Response in Attention Deficit Hyperactivity Disorder Unknown status NCT02074228 Phase 4 Methylphenidate (Concerta)
10 A Pharmacokinetic Study of Aptensio XR® (Methylphenidate Hydrochloride Extended-release) Capsules in Male or Female Pre-School Children 4 to Under 6 Years of Age With ADHD in Fed Condition Unknown status NCT02470234 Phase 4 Methylphenidate HCl ER Capsules
11 Association Between Motorcycle Accidents, Attention Deficit/Hyperactivity Disorder and Substance Use Disorder and Motorcycle Accidents Unknown status NCT00536419 Phase 4 Methylphenidate
12 Adjunctive Treatment With Divalproex or Risperidone for Aggression Refractory to Stimulant Monotherapy Among Children With ADHD Unknown status NCT00794625 Phase 4 Valproate;Risperidone;Placebo;Stimulant medication
13 The Assessment of Efficacy and Tolerability of Methylphenidate vs. Risperidone in the Treatment of Children and Adolescents With ADHD and Disruptive Disorders Unknown status NCT02063945 Phase 4 Methylphenidate;Risperidone
14 Assessment and Follow Up Study of Children and Adolescent With Bipolar Disorder Unknown status NCT01000402 Phase 4 Psychopharmacotherapy
15 Efficacy of Methylphenidate for Management of Long-Term Attention Problems After Pediatric Traumatic Brain Injury (TBI) Unknown status NCT01933217 Phase 4 Methylphenidate;Placebo
16 Methylphenidate Treatment of Children and Adolescents Diagnosed With ADHD and Its Influence on Comorbid Trichotillomania Unknown status NCT00552266 Phase 4 Methylphenidate
17 Effects of a Probiotic Supplement on Symptoms of ADHD and Anxiety in Children Unknown status NCT02545634 Phase 4
18 A Randomized, Double-Blind, Placebo-Controlled, Flexible-Dose Titration Study of Aptensio XR® in Children Ages 4 to Under 6 Years Diagnosed With Attention Deficit-Hyperactivity Disorder (ADHD) Unknown status NCT02683265 Phase 4 Aptensio XR;Placebo
19 Methylphenidate in Healthy Young Adults Unknown status NCT00815841 Phase 4 METHYLPHENIDATE
20 Phase 3 Reboxetine Treatment in Depressed Children and Adolescents an 8-Week, Open Study Unknown status NCT00426946 Phase 4 Reboxetine
21 Nicotine Treatment of Impulsivity in Parkinson's Disease: A Pilot Study Unknown status NCT01216904 Phase 4 nicotine patch;placebo
22 Efficacy of Concerta in Treating ADHD in Mothers of Children With ADHD Unknown status NCT00318981 Phase 4 Concerta
23 Levetiracetam Treatment of Children With Subclinical Sleep-Activated Epileptiform Activity (SSEA) - a Placebo Controlled Double-blind Cross-over-study Unknown status NCT00393614 Phase 4 levetiracetam
24 Phase IV Placebo-Controlled Study of Atomoxetine Hydrochloride in the Treatment of Adults With ADHD and Comorbid Social Anxiety Disorder Completed NCT00190879 Phase 4 Atomoxetine hydrochloride;placebo
25 A Randomized, Double-Blind, Crossover Comparison of Atomoxetine and Placebo in Child Outpatients With Attention-Deficit/Hyperactivity Disorder, Reading Disorder, or Comorbid Attention-Deficit/Hyperactivity Disorder and Reading Disorder. Completed NCT00191906 Phase 4 Atomoxetine Hydrochloride;placebo
26 A Pilot Study of Omega-3 Fatty Acid Supplementation to ADHD Medication in Children With ADHD and Deficits in Emotional Self-Regulation Completed NCT02204410 Phase 4 ADHD Medication
27 An Open-Label Study of Naltrexone in Adults With Attention Deficit Hyperactivity Disorder. Completed NCT01873729 Phase 4 Naltrexone
28 An Open-Label, Multicenter, Pilot Study of the Safety and Efficacy of Transitioning From a Stimulant Medication to Atomoxetine in Pediatric and Adolescent Outpatients With DSM-IV Attention-Deficit/Hyperactivity Disorder (ADHD) Completed NCT00485875 Phase 4 Atomoxetine Hydrochloride
29 A 3 Month Open-Label Study of Atomoxetine in Children With Attention-Deficit/Hyperactivity Disorder; Symptomatic and Functional Outcomes. Completed NCT00191633 Phase 4 Atomoxetine
30 Evaluation of Academic Performance in Asian Children Aged 8 to 11 Years With Attention-Deficit/Hyperactivity Disorder Treated With Atomoxetine Hydrochloride Completed NCT00471354 Phase 4 Atomoxetine
31 Open-Label Treatment With Atomoxetine Hydrochloride in Child and Adolescents With Attention-Deficit/Hyperactivity Disorder and Comorbid Dyslexia Completed NCT00191048 Phase 4 Atomoxetine
32 An Open-Label Pilot Study of Atomoxetine Hydrochloride to Evaluate Neuropsychological Function in Children Ages 6 to 10 Years With Attention-Deficit/Hyperactivity Disorder. Completed NCT00216918 Phase 4 Atomoxetine Hydrochloride
33 A Randomized, Double-blind Comparison of Atomoxetine Hydrochloride and Placebo for Symptoms of Attention-Deficit/Hyperactivity Disorder in Children and Adolescents With Autism Spectrum Disorder Completed NCT00380692 Phase 4 Atomoxetine;Placebo
34 Open-Label Treatment Trial to Assess the Short-Term Tolerability, Safety, and Efficacy of Methylphenidate Hydrochloride Extended-Release Liquid Formulation in High-Functioning Autism Spectrum Disorder Adults With Attention-Deficit/Hyperactivity Disorder Completed NCT02096952 Phase 4 Methylphenidate extended-release liquid formulation
35 A Double-Blind Placebo Controlled Study of Atomoxetine Hydrochloride for the Treatment of ADHD in Children and Adolescents With ADHD and Comorbid Dyslexia Completed NCT00607919 Phase 4 Atomoxetine;Placebo
36 A Randomized, Multi-center, Double-blind, Placebo-controlled, Cross-over Study Evaluating the Safety and Efficacy of Dex-Methylphenidate Extended Release 30 mg vs. 20 mg as Measured by SKAMP-Combined Scores in Children With Attention-Deficit/Hyperactivity Disorder (ADHD) in a Laboratory Classroom Setting. Completed NCT00776009 Phase 4 Dex-Methylphenidate hydrochloride Extended Release (Focalin® XR);Placebo
37 A Randomized, Double-Blind Comparison of the Time Course of Response to Two Extended-Release Oral Delivery Systems for Methylphenidate in Pediatric Patients With Attention Deficit Hyperactivity Disorder in an Analog Classroom Setting: The CoMACS Study Completed NCT00381758 Phase 4 Methylphenidate Extended Release Capsules
38 A Phase 4, Randomized, Double-blind, Multicenter, Parallel-group, Active-controlled, Dose-optimization Safety and Efficacy Study of SPD489 (VYVANSE®) Compared With OROS-MPH (CONCERTA®) With a Placebo Reference Arm, in Adolescents Aged 13-17 Years With Attention-deficit/Hyperactivity Disorder (ADHD) Completed NCT01552915 Phase 4 Lisdexamfetamine dimesylate;Methylphenidate Hydrochloride;Placebo
39 A Phase 4, Randomized, Double-blind, Multicenter, Parallel-group, Active-controlled, Forced-dose Titration, Safety and Efficacy Study of SPD489 (VYVANSE®) Compared With OROS-MPH (CONCERTA®) With a Placebo Reference Arm, in Adolescents Aged 13-17 Years With Attention-deficit/Hyperactivity Disorder (ADHD) Completed NCT01552902 Phase 4 Lisdexamfetamine dimesylate;Methylphenidate Hydrochloride;Placebo
40 A Randomized, Multi-center, Double-blind, Cross-over Study Comparing the Efficacy and Safety of Focalin® XR 20 mg Versus Placebo at the 0.5 Hour Timepoint (Post-dose) in Children (6-12 Years) With Attention-Deficit/Hyperactivity Disorder (ADHD) in a Laboratory Classroom Setting Completed NCT00564954 Phase 4 Dex-methylphenidate hydrochloride extended-release (Focalin XR);Placebo
41 A 40-Week, Phase 4, Double-Blind, Placebo-Controlled, Multicenter, Randomized-Withdrawal Study to Evaluate the Long-Term Efficacy and Safety of KAPVAY™ (Clonidine Hydrochloride) Extended-Release in Children and Adolescents With ADHD Completed NCT01439126 Phase 4 clonidine hydrochloride;Placebo
42 Evaluation of Continuous Symptom Treatment of ADHD: A Placebo-Controlled Double-Blind Assessment of Morning-Dosed or Evening-Dosed Strattera Completed NCT00486122 Phase 4 Atomoxetine Hydrochloride;Placebo
43 Maintenance of Benefit After 8-Week and 52-Week Treatment With Atomoxetine Hydrochloride in Adolescents With ADHD Completed NCT00191035 Phase 4 Atomoxetine
44 The Role of Adverse Environment Factors, Family Functioning and Parental Psychopathology in the Response to Treatment With Methylphenidate in Children and Adolescents With Attention Deficit/Hyperactivity Disorder Completed NCT00773916 Phase 4 Methylphenidate
45 Genetic Polymorphism of Drug Transporters in OROS-Methylphenidate Treatment in Children and Adolescents With Attention Deficit Hyperactivity Disorder(ADHD) Completed NCT00842127 Phase 4 OROS-methylphenidate (Concerta)
46 Association Between Norepinephrine Transporter Polymorphism and Response of Methylphenidate Completed NCT00757029 Phase 4
47 Effect of OROS-Methylphenidate (Concerta) on Different Domains of Attention and Working Memory in Children With Attention-Deficit/Hyperactivity Disorder Completed NCT00530257 Phase 4 Placebo;OROS-methylphenidate
48 Randomized Control Study of Concerta and Strattera on the Improvement of Executive Function in Attention Deficit Hyperactivity Disorder Children Completed NCT01065259 Phase 4 OROS MPH;Atomoxetine
49 A Double-Blind Study of Functional Outcomes With Atomoxetine-Hydrochloride and Placebo in Adult Outpatients With DSM-IV Attention-Deficit/Hyperactivity Disorder Completed NCT00190931 Phase 4 Atomoxetine Hydrochloride;placebo
50 A Phase 4, Double-Blind, Multi-Center, Placebo-Controlled, Randomized Withdrawal, Safety and Efficacy Study of SPD489 in Adults Aged 18-55 With Attention-Deficit/Hyperactivity Disorder (ADHD) Completed NCT00877487 Phase 4 SPD489 (Lisdexamfetamine dimesylate);Placebo

Search NIH Clinical Center for Attention Deficit-Hyperactivity Disorder

Inferred drug relations via UMLS 71 / NDF-RT 50 :


Amphetamine
AMPHETAMINE ADIPATE
Amphetamine aspartate
Amphetamine Sulfate
AMPHETAMINE/DEXTROAMPHETAMINE RESIN COMPLEX
atomoxetine
atomoxetine hydrochloride
Bupropion
Bupropion hydrobromide
Bupropion Hydrochloride
Clonidine
CLONIDINE HCL PWDR
Clonidine Hydrochloride
Desipramine
Desipramine Hydrochloride
dexmethylphenidate
dexmethylphenidate hydrochloride
Dextroamphetamine
DEXTROAMPHETAMINE ADIPATE
Dextroamphetamine saccharate
Dextroamphetamine Sulfate
Imipramine
Imipramine Hydrochloride
Imipramine pamoate
Methamphetamine
Methylphenidate
Methylphenidate Hydrochloride
modafinil
Nortriptyline
Nortriptyline Hydrochloride
Pemoline
Selegiline
selegiline hydrochloride
venlafaxine
Venlafaxine hydrochloride

Cochrane evidence based reviews: attention deficit disorder with hyperactivity

Genetic Tests for Attention Deficit-Hyperactivity Disorder

Genetic tests related to Attention Deficit-Hyperactivity Disorder:

# Genetic test Affiliating Genes
1 Attention Deficit Hyperactivity Disorder 29 DRD4 DRD5

Anatomical Context for Attention Deficit-Hyperactivity Disorder

MalaCards organs/tissues related to Attention Deficit-Hyperactivity Disorder:

40
Brain, Testes, Cortex, Heart, Prefrontal Cortex, Thyroid, Eye

Publications for Attention Deficit-Hyperactivity Disorder

Articles related to Attention Deficit-Hyperactivity Disorder:

(show top 50) (show all 23500)
# Title Authors PMID Year
1
Transmission disequilibrium testing of dopamine-related candidate gene polymorphisms in ADHD: confirmation of association of ADHD with DRD4 and DRD5. 61 56 6
14699430 2004
2
Association between the 5HT1B receptor gene (HTR1B) and the inattentive subtype of ADHD. 54 61 56
16197923 2006
3
Further evidence of the involvement of alpha-2A-adrenergic receptor gene (ADRA2A) in inattentive dimensional scores of attention-deficit/hyperactivity disorder. 54 61 56
16172611 2006
4
Sequence variation in the 3'-untranslated region of the dopamine transporter gene and attention-deficit hyperactivity disorder (ADHD). 54 61 56
16082693 2005
5
Temperament and character profiles and the dopamine D4 receptor gene in ADHD. 54 61 56
15863792 2005
6
Dopamine receptor D4 (DRD4) gene in Han Chinese children with attention-deficit/hyperactivity disorder (ADHD): increased prevalence of the 2-repeat allele. 54 61 56
15578612 2005
7
DAT1, DRD4, and DRD5 polymorphisms are not associated with ADHD in Dutch families. 54 61 56
15389755 2005
8
Joint analysis of the DRD5 marker concludes association with attention-deficit/hyperactivity disorder confined to the predominantly inattentive and combined subtypes. 54 61 6
14732906 2004
9
Association of the dopamine D4 receptor gene 7-repeat allele with neuropsychological test performance of children with ADHD. 54 61 56
14702261 2004
10
Is the alpha-2A adrenergic receptor gene (ADRA2A) associated with attention-deficit/hyperactivity disorder? 54 61 56
12815749 2003
11
Evidence for linkage of a tandem duplication polymorphism upstream of the dopamine D4 receptor gene (DRD4) with attention deficit hyperactivity disorder (ADHD). 54 61 6
11032387 2000
12
Identification of DNA variants in the SNAP-25 gene and linkage study of these polymorphisms and attention-deficit hyperactivity disorder. 54 61 56
10889551 2000
13
Mapping susceptibility loci in attention deficit hyperactivity disorder: preferential transmission of parental alleles at DAT1, DBH and DRD5 to affected children. 54 61 6
10208453 1999
14
Association of attention-deficit disorder and the dopamine transporter gene. 54 61 56
7717410 1995
15
Role for the membrane receptor guanylyl cyclase-C in attention deficiency and hyperactive behavior. 61 56
21835979 2011
16
GIT1 is associated with ADHD in humans and ADHD-like behaviors in mice. 61 56
21499268 2011
17
Forebrain overexpression of CK1delta leads to down-regulation of dopamine receptors and altered locomotor activity reminiscent of ADHD. 61 56
20145109 2010
18
Parent-of-origin effect and risk for attention-deficit/hyperactivity disorder: balancing the evidence against bias and chance findings. 61 56
16960815 2006
19
Heterozygosity for a protein truncation mutation of sodium channel SCN8A in a patient with cerebellar atrophy, ataxia, and mental retardation. 61 56
16236810 2006
20
A genome-wide scan for attention-deficit/hyperactivity disorder in 155 German sib-pairs. 61 56
16222334 2006
21
A common haplotype of the dopamine transporter gene associated with attention-deficit/hyperactivity disorder and interacting with maternal use of alcohol during pregnancy. 61 56
16389200 2006
22
Preferential transmission of paternal alleles at risk genes in attention-deficit/hyperactivity disorder. 61 56
16380908 2005
23
The SNAP25 gene as a susceptibility gene contributing to attention-deficit hyperactivity disorder. 61 56
16088329 2005
24
Catechol O-methyltransferase gene variant and birth weight predict early-onset antisocial behavior in children with attention-deficit/hyperactivity disorder. 61 56
16275815 2005
25
Attention-deficit/hyperactivity disorder in a population isolate: linkage to loci at 4q13.2, 5q33.3, 11q22, and 17p11. 61 56
15497111 2004
26
Attention deficit hyperactivity disorder: fine mapping supports linkage to 5p13, 6q12, 16p13, and 17p11. 61 56
15297934 2004
27
Genome-wide scan of reading ability in affected sibling pairs with attention-deficit/hyperactivity disorder: unique and shared genetic effects. 61 56
14625563 2004
28
Co-occurrence of ADHD and low IQ has genetic origins. 61 56
14681911 2004
29
Disruption of a novel member of a sodium/hydrogen exchanger family and DOCK3 is associated with an attention deficit hyperactivity disorder-like phenotype. 61 56
14569117 2003
30
Role of dopamine transporter genotype and maternal prenatal smoking in childhood hyperactive-impulsive, inattentive, and oppositional behaviors. 61 56
12915833 2003
31
A whole-genome scan in 164 Dutch sib pairs with attention-deficit/hyperactivity disorder: suggestive evidence for linkage on chromosomes 7p and 15q. 61 56
12679898 2003
32
A genomewide scan for attention-deficit/hyperactivity disorder in an extended sample: suggestive linkage on 17p11. 61 56
12687500 2003
33
The serotonin 5-HT1B receptor gene and attention deficit hyperactivity disorder. 61 56
12556913 2003
34
Genetic linkage of attention-deficit/hyperactivity disorder on chromosome 16p13, in a region implicated in autism. 61 56
12187510 2002
35
A genomewide scan for loci involved in attention-deficit/hyperactivity disorder. 61 56
11923911 2002
36
Attention-deficit/hyperactivity disorder (ADHD): feasibility of linkage analysis in a genetic isolate using extended and multigenerational pedigrees. 61 56
12081716 2002
37
Quantitative trait locus for reading disability on chromosome 6p is pleiotropic for attention-deficit/hyperactivity disorder. 61 56
11920845 2002
38
Serotonergic system and attention deficit hyperactivity disorder (ADHD): a potential susceptibility locus at the 5-HT(1B) receptor gene in 273 nuclear families from a multi-centre sample. 61 56
12192616 2002
39
The short DRD4 repeats confer risk to attention deficit hyperactivity disorder in a family-based design and impair performance on a continuous performance test (TOVA). 61 56
12192625 2002
40
Problems in the management of attention-deficit-hyperactivity disorder. 61 56
9878644 1999
41
Association and linkage of the dopamine transporter gene and attention-deficit hyperactivity disorder in children: heterogeneity owing to diagnostic subtype and severity. 61 56
9837830 1998
42
Genetic influences in childhood-onset psychiatric disorders: autism and attention-deficit/hyperactivity disorder. 61 56
9199546 1997
43
Comparison of diagnostic criteria for attention-deficit hyperactivity disorder in a county-wide sample. 61 56
8714320 1996
44
Cerebral glucose metabolism in adults with hyperactivity of childhood onset. 61 56
2233902 1990
45
Management of Attention-Deficit/Hyperactivity Disorder in Primary Care. 61 42
31703777 2019
46
An update on the pharmacokinetic considerations in the treatment of ADHD with long-acting methylphenidate and amphetamine formulations. 61 42
31581854 2019
47
Amphetamine extended-release oral suspension for attention-deficit/hyperactivity disorder. 61 42
31526076 2019
48
Genetic susceptibility to Parkinson's disease among South and North Indians: I. Role of polymorphisms in dopamine receptor and transporter genes and association of DRD4 120-bp duplication marker. 6
16816977 2006
49
No support for association between the dopamine transporter (DAT1) gene and ADHD. 56
16082688 2005
50
Genetics of population isolates. 56
12030885 2002

Variations for Attention Deficit-Hyperactivity Disorder

ClinVar genetic disease variations for Attention Deficit-Hyperactivity Disorder:

6 (show all 48) ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎
# Gene Name Type Significance ClinVarId dbSNP ID GRCh37 Pos GRCh38 Pos
1 MECP2 NM_001110792.2(MECP2):c.1200_1220delinsCTGAGCCCCAGGACTTGAGCA (p.Pro401_Ser407delinsTer)indel Pathogenic 189665 rs786205019 X:153296095-153296115 X:154030644-154030664
2 VPS13B NM_015243.2(VPS13B):c.1219C>T (p.Gln407Ter)SNV Pathogenic 56645 rs386834070 8:100146872-100146872 8:99134644-99134644
3 C12orf57 NM_138425.4(C12orf57):c.53-2A>GSNV Pathogenic 242885 rs1114167293 12:7053637-7053637 12:6944474-6944474
4 GNB5 NM_016194.4(GNB5):c.368C>T (p.Ser123Leu)SNV Pathogenic 254029 rs761399728 15:52446144-52446144 15:52153947-52153947
5 46;XY;t(8;10)(q13;p13)dnTranslocation Pathogenic 267850
6 46;XX;inv(7)(q11.23q36.3)dninversion Pathogenic 267882
7 46;XY;t(3;5)(q24;p15.3)dnTranslocation Pathogenic 267902
8 46;XY;t(5;15)(q11.2;q24)Translocation Pathogenic 267937
9 HIVEP1 NM_002114.4(HIVEP1):c.4089G>C (p.Met1363Ile)SNV Pathogenic 375377 rs776300630 6:12124117-12124117 6:12123884-12123884
10 CDK20 NM_001039803.2(CDK20):c.564G>A (p.Trp188Ter)SNV Pathogenic 375376 rs1057519438 9:90584834-90584834 9:87969919-87969919
11 SCAPER NM_020843.3(SCAPER):c.2973_2976del (p.Ile991Metfs)short repeat Pathogenic 417685 rs1555447569 15:76763655-76763658 15:76471314-76471317
12 CDRT4 , HS3ST3B1 , PMP22 , TEKT3 , TVP23C , TVP23C-CDRT4 GRCh37/hg19 17p12(chr17:14215739-15422582)copy number loss Pathogenic 523238 17:14215739-15422582
13 CDRT4 , HS3ST3B1 , PMP22 , TEKT3 , TVP23C , TVP23C-CDRT4 GRCh37/hg19 17p12(chr17:14215739-15422582)copy number loss Pathogenic 523259 17:14215739-15422582
14 subset of 47 genes: TBX1 GRCh37/hg19 22q11.21(chr22:18894835-21505417)copy number loss Pathogenic 523274 22:18894835-21505417
15 46;XY;t(3;18)(q13.31;q22.1)dnTranslocation Pathogenic 268039
16 MAP1B NM_005909.5(MAP1B):c.5368C>T (p.Arg1790Ter)SNV Pathogenic 638688 5:71494550-71494550 5:72198723-72198723
17 TCF20 NM_005650.3(TCF20):c.5725C>T (p.His1909Tyr)SNV Pathogenic/Likely pathogenic 590780 rs1569110700 22:42575639-42575639 22:42179633-42179633
18 C12orf4 NM_020374.4(C12orf4):c.639_640insACAA (p.Gln214fs)insertion Pathogenic/Likely pathogenic 183276 rs730882197 12:4634508-4634509 12:4525342-4525343
19 CHAF1B NM_005441.3(CHAF1B):c.496A>G (p.Ile166Val)SNV Likely pathogenic 183350 rs140630794 21:37769727-37769727 21:36397429-36397429
20 DRD5 DRD5, (CA)n MARKERundetermined variant risk factor 16766
21 DRD4 DRD4, 120-BP INSinsertion risk factor 16769
22 TMEM47 NM_031442.4(TMEM47):c.35G>C (p.Arg12Pro)SNV Likely pathogenic 242889 rs1114167296 X:34675112-34675112 X:34656995-34656995
23 MAGED2 NM_177433.3(MAGED2):c.1003del (p.Gln335fs)deletion Likely pathogenic 242888 rs1114167295 X:54838602-54838602 X:54812169-54812169
24 KIF5B NM_004521.3(KIF5B):c.2252A>G (p.His751Arg)SNV Likely pathogenic 242891 rs1114167297 10:32308840-32308840 10:32019912-32019912
25 46;XX;t(10;14)(p13;q21)dnTranslocation Likely pathogenic 267875
26 46;X;t(Y;16)(q11.23;p11.2);t(6;21)(p21.3;p13)dnTranslocation Likely pathogenic 267834
27 CACNA1A NM_001127221.1(CACNA1A):c.*478_*483deldeletion Conflicting interpretations of pathogenicity 598990 rs1568415991 19:13318377-13318382 19:13207563-13207568
28 CLCN2 NM_004366.6(CLCN2):c.775G>A (p.Val259Ile)SNV Uncertain significance 598991 rs757549500 3:184075273-184075273 3:184357485-184357485
29 DEAF1 NM_021008.3(DEAF1):c.667G>A (p.Gly223Ser)SNV Uncertain significance 373980 rs1057518811 11:686995-686995 11:686995-686995
30 CSMD2 NM_052896.4(CSMD2):c.2551A>G (p.Ile851Val)SNV Uncertain significance 690311 1:34190974-34190974 1:33725373-33725373
31 QARS1 NM_005051.3(QARS1):c.1412G>A (p.Cys471Tyr)SNV Uncertain significance 690310 3:49137057-49137057 3:49099624-49099624
32 TBC1D9 NM_015130.3(TBC1D9):c.3535C>T (p.His1179Tyr)SNV Uncertain significance 690308 4:141543615-141543615 4:140622461-140622461
33 DAGLA NM_006133.3(DAGLA):c.3049G>C (p.Asp1017His)SNV Uncertain significance 690309 11:61511881-61511881 11:61744409-61744409
34 WDR83 NM_001099737.3(WDR83):c.379G>C (p.Gly127Arg)SNV Uncertain significance 690312 19:12781425-12781425 19:12670611-12670611
35 46;XX;t(9;19)(q22.3;q13.1)dnTranslocation Uncertain significance 267844
36 46;XY;t(4;14)(p15.32;q32.1)dnTranslocation Uncertain significance 267808
37 46;XY;t(6;11)(q23;q21)or(q25;q21)dnTranslocation Uncertain significance 267823
38 46;XY;t(1;3)(p22;q21)dnTranslocation Uncertain significance 267862
39 46;XY;t(2;11)(q31;q13.5)patTranslocation Uncertain significance 267865
40 covers 13 genes, none of which curated to show dosage sensitivity GRCh37/hg19 3q29(chr3:195457650-196263123)copy number loss Uncertain significance 523280 3:195457650-196263123
41 LOC101928834 , MALRD1 , PLXDC2 deletion Uncertain significance 559400 10:19906553-20105884 10:19617624-19816955
42 46;XY;inv(2)(q11.2q24.2)dninversion Uncertain significance 267939
43 46;XX;t(2;5)(q33;p15.3)Translocation Uncertain significance 267966
44 46;X;inv(X)(q27q28)inversion Uncertain significance 267971
45 46;XY;t(4;7)(q31;q22)dnTranslocation Uncertain significance 267911
46 46;XY;t(12;14)(q15;q13)matTranslocation Uncertain significance 267936
47 46;XY;t(20;22)(q13.3;q11.2)Translocation Uncertain significance 267893
48 MECP2 NM_001110792.2(MECP2):c.1351G>A (p.Ala451Thr)SNV Benign/Likely benign 143458 rs61753973 X:153295964-153295964 X:154030513-154030513

Copy number variations for Attention Deficit-Hyperactivity Disorder from CNVD:

7 (show top 50) (show all 84)
# CNVD ID Chromosome Start End Type Gene Symbol CNVD Disease
1 34465 1 56053497 56064495 Deletion USP24 Attention deficit hyperactivity disorder
2 34466 1 56053497 56064495 Deletion USP24e Attention deficit hyperactivity disorder
3 36125 1 72317292 72328395 Duplication NEGR1 Attention deficit hyperactivity disorder
4 49516 11 107520009 107885084 Duplication C11orf65 Attention deficit hyperactivity disorder
5 49517 11 107520009 107885084 Duplication EXPH5 Attention deficit hyperactivity disorder
6 49518 11 107520009 107885084 Duplication KDELC2 Attention deficit hyperactivity disorder
7 60337 11 85300000 92300000 Deletion GRM5 Attention deficit hyperactivity disorder
8 60583 11 88269449 88351661 Deletion GRM5 Attention deficit hyperactivity disorder
9 60585 11 88269449 88351661 Het ACAT1 Attention deficit hyperactivity disorder
10 60586 11 88269449 88351661 Het ATM Attention deficit hyperactivity disorder
11 60587 11 88269449 88351661 Het GRM5 Attention deficit hyperactivity disorder
12 60588 11 88269449 88351661 Het NPAT Attention deficit hyperactivity disorder
13 63163 12 115300000 116700000 Duplicated NOS1 Attention deficit hyperactivity disorder
14 69603 12 55902280 55923860 Deletion NDUFA4L2 Attention deficit hyperactivity disorder
15 69604 12 55902280 55923860 Deletion NXPH4 Attention deficit hyperactivity disorder
16 69605 12 55902280 55923860 Deletion SHMT2 Attention deficit hyperactivity disorder
17 69606 12 55902280 55923860 Deletion STAC3 Attention deficit hyperactivity disorder
18 75846 13 24844208 25493420 Duplication or deletion ATP8A2 Attention deficit hyperactivity disorder
19 76965 13 38815028 39075356 Duplication or deletion LHFP Attention deficit hyperactivity disorder
20 78033 13 48967801 49001118 Duplication or deletion PHF11 Attention deficit hyperactivity disorder
21 78043 13 49004082 49057720 Duplication or deletion RCBTB1 Attention deficit hyperactivity disorder
22 79472 13 72254230 72488592 Duplication or deletion PIBF1 Attention deficit hyperactivity disorder
23 91412 15 30110017 30248527 Deletion CHRNA7 Attention deficit hyperactivity disorder
24 99563 16 27600000 34400000 Deleted ERK1 Attention deficit hyperactivity disorder
25 99685 16 28100000 34600000 Deletion CORO1A Attention deficit hyperactivity disorder
26 101713 16 45500000 51200000 Duplicated ZNF423 Attention deficit hyperactivity disorder
27 103489 16 6072599 6783832 Duplication A2BP1 Attention deficit hyperactivity disorder
28 106366 16 87694595 87778383 Deletion CDH15 Attention deficit hyperactivity disorder
29 109330 17 25613604 26191779 Duplication BLMH Attention deficit hyperactivity disorder
30 117083 17 71112486 71120734 Deletion Attention deficit hyperactivity disorder
31 122044 18 52000000 54400000 Duplicated NEDD4L Attention deficit hyperactivity disorder
32 123018 18 65358832 65367619 Deletion DOK6 Attention deficit hyperactivity disorder
33 125924 19 15992679 15997923 Deletion LOC126536 Attention deficit hyperactivity disorder
34 127980 19 38427720 38444834 Deletion SLC7A10 Attention deficit hyperactivity disorder
35 127981 19 38427720 38444834 Deletion SLC7A10e Attention deficit hyperactivity disorder
36 132645 19 59423491 59428132 Duplication LILRB3 Attention deficit hyperactivity disorder
37 132646 19 59423491 59428132 Duplication LIR-3 Attention deficit hyperactivity disorder
38 136696 2 132200000 134800000 Deleted NAP5 Attention deficit hyperactivity disorder
39 139372 2 1792886 2335045 Duplication or deletion MYT1L Attention deficit hyperactivity disorder
40 146272 2 47600000 52700000 Deleted NRXN1 Attention deficit hyperactivity disorder
41 146517 2 50145643 51259674 Duplication or deletion NRXN1 Attention deficit hyperactivity disorder
42 146826 2 55088956 55239201 Duplication RTN4 Attention deficit hyperactivity disorder
43 148301 2 75400000 83700000 Deleted CTNNA2 Attention deficit hyperactivity disorder
44 148598 2 81419297 81446082 Duplication CTNNA2 Attention deficit hyperactivity disorder
45 148599 2 81419297 81446082 Duplication CTNNA2e Attention deficit hyperactivity disorder
46 154924 20 5000000 9000000 Deleted BMP2 Attention deficit hyperactivity disorder
47 164095 22 34870070 34916870 Het APOL3 Attention deficit hyperactivity disorder
48 164096 22 34870070 34916870 Het APOL4 Attention deficit hyperactivity disorder
49 164674 22 38384374 38403731 Deletion CACNA1I Attention deficit hyperactivity disorder
50 166998 3 111722434 117006477 Deletion Attention deficit hyperactivity disorder

Expression for Attention Deficit-Hyperactivity Disorder

Search GEO for disease gene expression data for Attention Deficit-Hyperactivity Disorder.

Pathways for Attention Deficit-Hyperactivity Disorder

Pathways related to Attention Deficit-Hyperactivity Disorder according to KEGG:

36
# Name Kegg Source Accession
1 Dopaminergic synapse hsa04728
2 Serotonergic synapse hsa04726
3 Neuroactive ligand-receptor interaction hsa04080

GO Terms for Attention Deficit-Hyperactivity Disorder

Biological processes related to Attention Deficit-Hyperactivity Disorder according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 dopamine receptor signaling pathway GO:0007212 9.37 GNB5 DRD4
2 synaptic transmission, dopaminergic GO:0001963 9.32 DRD5 DRD4
3 negative regulation of voltage-gated calcium channel activity GO:1901386 9.26 GNB5 DRD4
4 dopamine metabolic process GO:0042417 9.16 DRD4 COMT
5 regulation of dopamine metabolic process GO:0042053 8.96 SLC6A3 DRD4
6 dopamine catabolic process GO:0042420 8.62 SLC6A3 COMT

Molecular functions related to Attention Deficit-Hyperactivity Disorder according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 dopamine neurotransmitter receptor activity GO:0004952 8.96 DRD5 DRD4
2 dopamine binding GO:0035240 8.8 SLC6A3 DRD5 DRD4

Sources for Attention Deficit-Hyperactivity Disorder

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
19 FMA
28 GO
29 GTR
30 HMDB
31 HPO
32 ICD10
33 ICD10 via Orphanet
34 ICD9CM
35 IUPHAR
36 KEGG
37 LifeMap
39 LOVD
41 MedGen
43 MeSH
44 MESH via Orphanet
45 MGI
48 NCI
49 NCIt
50 NDF-RT
53 NINDS
54 Novoseek
56 OMIM
57 OMIM via Orphanet
61 PubMed
63 QIAGEN
68 SNOMED-CT via HPO
69 TGDB
70 Tocris
71 UMLS
72 UMLS via Orphanet
Content
Loading form....